Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $708000.0.

  • Corvus Pharmaceuticals' Change in Accured Expenses rose 89550.56% to $708000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 53779.07%. This contributed to the annual value of -$245000.0 for FY2024, which is 9315.26% up from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Change in Accured Expenses stood at $708000.0, which was up 89550.56% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Corvus Pharmaceuticals' Change in Accured Expenses registered a high of $2.2 million during Q3 2022, and its lowest value of -$1.9 million during Q1 2023.
  • For the 4-year period, Corvus Pharmaceuticals' Change in Accured Expenses averaged around -$90666.7, with its median value being $98000.0 (2023).
  • Per our database at Business Quant, Corvus Pharmaceuticals' Change in Accured Expenses plummeted by 40103.9% in 2023 and then soared by 89550.56% in 2025.
  • Quarter analysis of 4 years shows Corvus Pharmaceuticals' Change in Accured Expenses stood at -$1.0 million in 2022, then soared by 42.37% to -$589000.0 in 2023, then rose by 16.81% to -$490000.0 in 2024, then skyrocketed by 244.49% to $708000.0 in 2025.
  • Its Change in Accured Expenses was $708000.0 in Q3 2025, compared to $1.1 million in Q2 2025 and $146000.0 in Q1 2025.